Doxorubicin Toxicity
Authors: SEWA S. LEGHA
Journal: Annals of Internal Medicine (1981)

Letters and Corrections1 October 1981Doxorubicin ToxicitySEWA S. LEGHA, M.D., ROBERT S. BENJAMIN, M.D.SEWA S. LEGHA, M.D.Search for more papers by this author, ROBERT S. BENJAMIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-95-4-520 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: In their excellent paper "Doxorubicin Cardiotoxicity: Assessment of Late Left Ventricular Dysfunction by Radionuclide Cineangiography," Gottdiener and associates (1) have described persistent left ventricular dysfunction in patients treated with cumulative doses of doxorubicin from 480 to 550 mg/m2 of body surface area. Because the left ventricular dysfunction was persistent at 30 months from the last dose of doxorubicin and sequential studies in 13 patients done 6 to 15 months after initial evaluation showed persistent depression of the average ejection fraction value, the authors concluded that such abnormalities may persist for years.Although these findings are of interest,...References1. GOTTDIENERMATHISENBORER JDJ. Doxorubicin cardiotoxicity assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94(Part 1):430-5. LinkGoogle Scholar2. SINGERNARAHARARITCHIEHAMILTONKENNEDY JKJGJ. Time and dose dependent changes in ejection fractions determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep. 1978;62:945-8. MedlineGoogle Scholar3. BLOOMBINIWILLIAMSSONLEYGRIBBIN KRCMM. Echocardiography in adriamycin cardiotoxicity. Cancer. 1978;41:1265-9. CrossrefMedlineGoogle Scholar4. GOORINBOROGOLDMAN AWA. Natural history in children of congestive heart failure secondary to adriamycin cardiomyopathy. Proc Am Assoc Cancer Res/Am Soc Clin Oncol. 1979;20:328. Abstract. Google Scholar5. ALEXANDERDAINIAKBERGER JNJ. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med. 1979;300:278-83. CrossrefMedlineGoogle Scholar6. LEGHABENJAMINMACKAY SRB. Reutilization of adriamycin in previously treated patients. Proc Am Assoc Cancer Res/Am Soc Clin Oncol. 1981;22:534. Abstract Google Scholar1. SINGERNARAHARARITCHIEHAMILTONKENNEDY JKJGJ. Time and dose dependent changes in ejection fractions determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep. 1978;62:945-8. MedlineGoogle Scholar2. BLOOMBINIWILLIAMSSONLEYGRIBBIN KRCMM. Echocardiography in adriamycin cardiotoxicity. Cancer. 1978;41:1265-9. CrossrefMedlineGoogle Scholar3. ALEXANDERDAINIAKBERGER JNJ. Serial assessment of doxorubin cardiotoxicity with quantitative radionuclide angiography. N Engl J Med. 1979;300:278-83. CrossrefMedlineGoogle Scholar4. GOORINBOROGOLDMAN AWA. Natural history in children of congestive heart failure secondary to adriamycin cardiomyopathy. Proc Am Assoc Cancer Res/Am Soc Clin Oncol. 1979;20:328. Abstract. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: M. D. Anderson Hospital and Tumor Institute Houston, TX 77030 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1981Volume 95, Issue 4Page: 520-521KeywordsBody surface areaEjection fractionToxicity Issue Published: 1 October 1981 PDF DownloadLoading ...